Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). Both autoimmune diseases and malaria have been known to be affected by DHODH.
DHODHs are divided into two families based on localization and the electron acceptor: While family 2 members are membrane proteins localized to the inner mitochondrial membrane, family 1 members are soluble proteins localized to the cytosol. Families 1A and 1B, which use fumarate and NAD+ as their respective electron acceptors, are further divided into families 1. Respiratory quinones are used by DHODH enzymes in family 2 as electron acceptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71993 | (E/Z)-Ginkgolic acid C17:2 (ginkgolic acid C17:2) | 102811-39-2 | (E/Z)-Ginkgolic acid C17:2 is developed from Ginkgo biloba and targets human dihydroorotate dehydrogenase (DHODH). |
|
V2473 | AG-636 | 1623416-31-8 | AG 636 (AG636; AG-636) is a novel,potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor (IC50=17 nM) which has strong anticancer effects. |
|
V55156 | Ascochlorin A (Acremochlorin A) | 2550720-02-8 | Ascochlorin A is a novel and potent hDHODH inhibitor (KD = 3.29 μM) studied in triple-negative breast cancer. |
|
V4172 | BAY-2402234 | 2225819-06-5 | BAY-2402234 is a novel, potent/low-nanomolar and selective inhibitor of dihydroorotate dehydrogenase(DHODH) that has the potentialfor the treatment of myeloid malignancies. |
|
V52260 | CHIKV-IN-2 | 2361289-44-1 | CHIKV-IN-2 is a potent inhibitor against chikungunya virus (CHIKV) with excellent cellular antiviral effect (EC90=270 nM) and improved liver microsomal stability. |
|
V52180 | DHODH-IN-16 | 2511248-11-4 | DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor (antagonist) with IC50 of 0.396 nM for human DHODH. |
|
V71992 | DHODH-IN-17 | 16344-26-6 | DHODH-IN-17, as a 2-anilinoylnicotinic acid, is a human DHODH inhibitor (IC50=0.40 μM). |
|
V72001 | DHODH-IN-18 | 2685799-97-5 | DHODH-IN-18 is a human DHODH inhibitor (IC50 = 0.2 nM) |
|
V72002 | DHODH-IN-21 | 2450341-39-4 | DHODH-IN-21 (compound 19) is an orally bioactive, selective dihydrolactate dehydrogenase (DHODH) inhibitor (antagonist) with IC50 of 1.1 nM. |
|
V71994 | DHODH-IN-23 | 1346705-53-0 | DHODH-IN-23 (Compound A) is an orally bioactive DHODH inhibitor that may be utilized in cancer-related research. |
|
V52154 | DSM502 | 2426616-55-7 | DSM502 is a pyrrole-based inhibitor of dihydroorotate dehydrogenase (DHODH). |
|
V52153 | DSM705 | 2653225-38-6 | DSM705 is a pyrrole-based inhibitor of dihydroorotate dehydrogenase (DHODH). |
|
V71999 | hDHODH-IN-11 | 2396653-34-0 | hDHODH-IN-11 is a potent inhibitor of human dihydrorotamate dehydrogenase (hDHODH) with IC50 of 7.2 nM. |
|
V79740 | hDHODH-IN-13 | hDHODH-IN-13 is an inhibitor (blocker/antagonist) of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 173.4 nM. | |
|
V71991 | hDHODH-IN-14 | 881826-17-1 | hDHODH-IN-14 (compound 14) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor (antagonist) with IC50 of 0.469 μM. |
|
V71995 | hDHODH-IN-8 | 2757405-31-3 | hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 16 nM. |
|
V71998 | Indoluidin E | 2763081-76-9 | Indoluidin E selectively inhibits DHODH and inhibits cancer/tumor cell growth. |
|
V71996 | Leflunomide-d4 (Leflunomide d4) | 1189987-23-2 | Leflunomide-d4 is the deuterated form of Leflunomide. |
|
V2626 | ML390 | 2029049-79-2 | ML390 is a novel potent inhibitor of human DHODH (Dihydroorotate dehydrogenase) that induces differentiation in acute myeloid leukemia (AML) with EC50 of 1.8μM, 8.8μM, 6.5μM, and 0.56μM in ER-HOX-GFP, U937, THP-1 cells and DHODH enzyme, respectively. |
|
V2242 | PfDHODH-IN-2 | 425629-94-3 | Desription: PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a Novel and potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
